Wells Fargo & Company reissued their outperform rating on shares of Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT) in a research report sent to investors on Wednesday.

A number of other analysts have also recently commented on ICPT. Wedbush reissued an outperform rating and issued a $253.00 price target on shares of Intercept Pharmaceuticals in a research note on Friday, August 25th. Credit Suisse Group set a $201.00 price target on Intercept Pharmaceuticals and gave the stock a buy rating in a research note on Saturday, June 3rd. Cantor Fitzgerald reissued an underweight rating and issued a $69.00 price target (up from $60.00) on shares of Intercept Pharmaceuticals in a research note on Monday, July 31st. ValuEngine raised Intercept Pharmaceuticals from a strong sell rating to a sell rating in a research note on Friday, June 2nd. Finally, BidaskClub lowered Intercept Pharmaceuticals from a buy rating to a hold rating in a research note on Friday, August 4th. One research analyst has rated the stock with a sell rating, five have assigned a hold rating, thirteen have issued a buy rating and one has given a strong buy rating to the stock. The company has a consensus rating of Buy and a consensus target price of $207.75.

Intercept Pharmaceuticals (NASDAQ:ICPT) opened at 94.88 on Wednesday. Intercept Pharmaceuticals has a 52-week low of $85.88 and a 52-week high of $172.95. The firm’s market cap is $2.38 billion. The firm has a 50-day moving average of $108.47 and a 200-day moving average of $116.36.

Intercept Pharmaceuticals (NASDAQ:ICPT) last posted its quarterly earnings data on Monday, July 31st. The biopharmaceutical company reported ($3.46) EPS for the quarter, topping analysts’ consensus estimates of ($3.62) by $0.16. The firm had revenue of $30.89 million during the quarter, compared to analysts’ expectations of $27.50 million. Intercept Pharmaceuticals had a negative return on equity of 135.24% and a negative net margin of 543.35%. The firm’s quarterly revenue was up 459.6% compared to the same quarter last year. During the same quarter last year, the business posted ($3.14) EPS. Equities analysts anticipate that Intercept Pharmaceuticals will post ($14.06) EPS for the current year.

ILLEGAL ACTIVITY NOTICE: This report was first published by Daily Political and is owned by of Daily Political. If you are viewing this report on another website, it was illegally stolen and republished in violation of U.S. and international copyright and trademark laws. The legal version of this report can be accessed at https://www.dailypolitical.com/2017/09/17/intercept-pharmaceuticals-inc-icpt-receives-outperform-rating-from-wells-fargo-company.html.

In related news, Director Daniel G. Welch sold 217 shares of the firm’s stock in a transaction dated Thursday, July 20th. The stock was sold at an average price of $126.76, for a total transaction of $27,506.92. Following the sale, the director now directly owns 3,710 shares in the company, valued at approximately $470,279.60. The sale was disclosed in a document filed with the SEC, which is accessible through this link. Also, insider Lisa Bright sold 394 shares of the firm’s stock in a transaction dated Monday, July 3rd. The shares were sold at an average price of $121.33, for a total value of $47,804.02. Following the sale, the insider now owns 23,619 shares in the company, valued at $2,865,693.27. The disclosure for this sale can be found here. Insiders sold a total of 48,013 shares of company stock worth $6,198,747 over the last ninety days. Corporate insiders own 9.20% of the company’s stock.

Large investors have recently made changes to their positions in the stock. Oppenheimer & Co. Inc. raised its holdings in shares of Intercept Pharmaceuticals by 9.0% during the 1st quarter. Oppenheimer & Co. Inc. now owns 2,152 shares of the biopharmaceutical company’s stock valued at $244,000 after buying an additional 178 shares during the period. Dynamic Technology Lab Private Ltd purchased a new stake in shares of Intercept Pharmaceuticals during the 1st quarter valued at about $414,000. Geode Capital Management LLC raised its holdings in shares of Intercept Pharmaceuticals by 12.8% during the 1st quarter. Geode Capital Management LLC now owns 144,130 shares of the biopharmaceutical company’s stock valued at $16,301,000 after buying an additional 16,392 shares during the period. Sphera Funds Management LTD. raised its holdings in shares of Intercept Pharmaceuticals by 100.0% during the 2nd quarter. Sphera Funds Management LTD. now owns 30,000 shares of the biopharmaceutical company’s stock valued at $3,632,000 after buying an additional 15,000 shares during the period. Finally, Van ECK Associates Corp raised its holdings in shares of Intercept Pharmaceuticals by 9.2% during the 1st quarter. Van ECK Associates Corp now owns 25,550 shares of the biopharmaceutical company’s stock valued at $2,890,000 after buying an additional 2,161 shares during the period. Institutional investors and hedge funds own 82.19% of the company’s stock.

Intercept Pharmaceuticals Company Profile

Intercept Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutics to treat non-viral, progressive liver diseases. The Company’s product candidates have the potential to treat orphan and more prevalent diseases for which there are limited therapeutic solutions.

Analyst Recommendations for Intercept Pharmaceuticals (NASDAQ:ICPT)

Receive News & Ratings for Intercept Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intercept Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.